S128: A RANDOMISED COMPARISON OF CPX-351 AND FLAG-IDA IN HIGH RISK ACUTE MYELOID LEUKAEMIA. RESULTS FROM THE NCRI AML19 TRIAL

書目詳細資料
發表在:	HemaSphere
Main Authors:	N. Russell, C. Wilhelm-Benartzi, S. Knapper, L. Batten, J Canham, E. Hinson, U. Malthe Overgaard, J. Othman, R. Dillon, P. Mehta, P. Kottaridis, J. Cavenagh, C. Hemmaway, C. Arnold, M. Dennis
格式:	Article
語言:	英语
出版:	Wiley 2022-06-01
在線閱讀:	http://journals.lww.com/10.1097/01.HS9.0000843404.12756.f4

相似書籍

S134: FLAG-IDA COMBINED WITH GEMTUZUMAB OZOGAMICIN (GO) REDUCED MRD LEVELS AND IMPROVED OVERALL SURVIVAL IN NPM1MUT AML INDEPENDENT OF FLT3 AND MRD STATUS, RESULTS FROM THE AML19 TRIAL
由: Nigel Russell, et al.
出版: (2023-08-01)

S126: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. RESULTS FROM THE NCRI AML19 “MIDOTARG” PILOT TRIAL
由: N. Russell, et al.
出版: (2022-06-01)

P484: GEMTUZUMAB-BASED INDUCTION CHEMOTHERAPY COMBINED WITH MIDOSTAURIN FOR FLT3 MUTATED AML. UPDATED TOXICITY AND INTERIM SURVIVAL ANALYSIS FROM THE NCRI AML19V2 “MIDOTARG” PILOT TRIAL
由: Nigel Russell, et al.
出版: (2023-08-01)

P500: A REAL WORLD MULTI CENTRE STUDY OF CPX-351 REVEALS NO DIFFERENCE IN OVERALL SURVIVAL WHEN COMPARED WITH FLAG-IDA AND 3 + 7 IN HIGH RISK AML.
由: C. Andrews, et al.
出版: (2022-06-01)

P503: A RANDOMISED TRIAL OF MOLECULAR MONITORING VERSUS STANDARD CLINICAL CARE IN YOUNGER ADULTS WITH ACUTE MYELOID LEUKAEMIA: RESULTS FROM THE UK NCRI AML17 AND AML19 STUDIES
由: Nicola Potter, et al.
出版: (2023-08-01)

CPX-351 in FLT3-mutated acute myeloid leukemia
由: Claire Andrews, et al.
出版: (2023-11-01)

S131: A RANDOMISED ASSESSMENT OF THE SEQUENTIAL ADDITION OF THE KINASE INHIBITOR QUIZARTINIB TO INTENSIVE CHEMOTHERAPY IN OLDER ACUTE MYELOID LEUKAEMIA (AML) PATIENTS: RESULTS FROM THE NCRI AML18 TRIAL
由: Steven Knapper, et al.
出版: (2023-08-01)

Cardiotoxicity of CPX-351 in children and adolescents with relapsed AML: a Children's Oncology Group report
由: Kasey J. Leger, et al.
出版: (2024-06-01)

P074 | CPX-351 IN SECONDARY ACUTE MYELOID LEUKEMIA: A REAL LIFE REGIONAL MULTICENTER EXPERIENCE.
由: A.L. Piccioni, et al.
出版: (2025-09-01)

DP091 | EFFICACY OF CPX-351 IN SECONDARY ACUTE MYELOID LEUKEMIA DEFINED ACCORDING TO WHO 2022 CLASSIFICATION.
由: F. Guolo, et al.
出版: (2025-09-01)

Lower cardiotoxicity of CPX-351 relative to daunorubicin plus cytarabine free-drug combination in hiPSC-derived cardiomyocytes in vitro
由: Marie C. Fortin, et al.
出版: (2023-11-01)

Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy
由: Geoffrey L. Uy, et al.
出版: (2024-12-01)

P535: UPDATES FROM ITALIAN MULTICENTER REAL-LIFE EXPERIENCE ON CPX-351 THERAPY IN YOUNG PATIENTS (<60 YEARS OLD).
由: B. Garibaldi, et al.
出版: (2022-06-01)

P508: REAL LIFE EXPERIENCE USING FRONT-LINE CPX-351 FOR THERAPY-RELATED AND AML-MRC: RESULTS FROM THE SPANISH PETHEMA REGISTRY.
由: T. Bernal, et al.
出版: (2022-06-01)

P574: CPX-351 COMBINED WITH HEMATOPOIETIC CELL TRANSPLANTATION WITH REGULATORY AND CONVENTIONAL T CELL IMMUNOTHERAPY FOR HIGH-RISK ACUTE MYELOID LEUKEMIA
由: S. Sciabolacci, et al.
出版: (2022-06-01)

The Clinical Safety and Efficacy of Cytarabine and Daunorubicin Liposome (CPX‐351) in Acute Myeloid Leukemia Patients: A Systematic Review
由: Abdulwahab M. Alzahrani, et al.
出版: (2025-05-01)

P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA
由: Joshua D. Mitchell, et al.
出版: (2023-08-01)

DP031 | PROGNOSTIC IMPACT OF HIGH-RISK MUTATIONS IN SECONDARY AML TREATED WITH CPX-351: A FOCUS ON MOLECULAR PREDICTORS OF RESPONSE AND SURVIVAL
由: C. Riva, et al.
出版: (2025-09-01)

P539: PROGNOSTIC RELEVANCE OF MINIMAL RESIDUAL DISEASE IN THERAPY RELATED AND SECONDARY ACUTE MYELOID LEUKEMIA RECEIVING CPX-351 OR FLUDARABINE-BASED INDUCTION.
由: F. Guolo, et al.
出版: (2022-06-01)

A Phase 2 study of CPX‐351 in combination with venetoclax in patients with newly diagnosed high‐risk acute myeloid leukemia
由: Wei‐Ying Jen, et al.
出版: (2025-10-01)

CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases
由: Rimal Ilyas, et al.
出版: (2023-02-01)

C086 | CHARACTERIZATION OF TP53 MUTATED ACUTE MYELOID LEUKEMIA TREATED WITH CPX-351: SUBANALYSIS FROM A LARGE REAL WORLD ITALIAN STUDY
由: E. Todisco, et al.
出版: (2025-09-01)

DP090 | CPX-351 LEADS TO HIGH RESPONSE RATES AND DURABLE OUTCOMES IN NPM1 MUTATED ACUTE MYELOID LEUKEMIA: AN ITALIAN MULTICENTRIC RETROSPECTIVE STUDY
由: F. Grimaldi, et al.
出版: (2025-09-01)

Efficacy of combining dasatinib and FLAG-IDA for patients with chronic myeloid leukemia in blastic transformation
由: Dragana Milojkovic, et al.
出版: (2012-03-01)

PB1763: THE CELLULAR UPTAKE OF CPX-351 BY SCAVENGER RECEPTOR CLASS B TYPE 1-MEDIATED NONENDOCYTIC PATHWAY IN LEUKEMIA CELLS.
由: Hiroaki Araie, et al.
出版: (2023-08-01)

P515: LOWER-INTENSITY CPX-351 + VENETOCLAX FOR PATIENTS WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA WHO ARE UNFIT FOR INTENSIVE CHEMOTHERAPY
由: G. L. Uy, et al.
出版: (2022-06-01)

V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML
由: Vinod A. Pullarkat, et al.
出版: (2025-11-01)

Long-term real-world evidence of CPX-351 of high-risk patients with AML identified high rate of negative MRD and prolonged OS
由: Thomas Cluzeau, et al.
出版: (2025-02-01)

Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm
由: Roland B. Walter, et al.
出版: (2018-03-01)

Real-world experience with first-line CPX-351 treatment in patients with acute myeloid leukemia – long-term follow-up with focus on younger patients
由: Christina Rautenberg, et al.
出版: (2025-04-01)

P513: CPX-351 TREATMENT FOR ACUTE MYELOID LEUKEMIA IN ENGLAND: REAL-WORLD OUTCOMES IN ADULTS AGED <60 YEARS VERSUS ≥60 YEARS
由: A. Legg, et al.
出版: (2022-06-01)

Dasatinib and FLAG-IDA Is an Effective Therapy for Initial Myeloid Blast Crisis but Involves a High Risk of Opportunistic Infections
由: Jorge Labrador, et al.
出版: (2020-01-01)

FIVE-YEAR FINAL RESULTS OF A PHASE 3 STUDY OF CPX-351 VERSUS 7+3 IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK/SECONDARY ACUTE MYELOID LEUKEMIA (AML)
由: J.E. Lancet, et al.
出版: (2020-11-01)

PB1879: EFFICACY AND SAFETY OF CPX-351 COMPARED TO STANDARD OF CARE CHEMOTHERAPY IN A REAL-LIFE SETTING: SUPPORTING PREVIOUS EVIDENCE AND FACING NEW CHALLENGES
由: Beatrice Manghisi, et al.
出版: (2023-08-01)

Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry
由: Teresa Bernal, et al.
出版: (2023-07-01)

P514: V-FAST MASTER TRIAL: PRELIMINARY RESULTS OF TREATMENT WITH CPX-351 PLUS MIDOSTAURIN IN ADULTS WITH NEWLY DIAGNOSED FLT3-MUTATED ACUTE MYELOID LEUKEMIA
由: J. McCloskey, et al.
出版: (2022-06-01)

Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia
由: N Yalman, et al.
出版: (2000-07-01)

Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial
由: Andrew R. Pettitt, et al.
出版: (2020-02-01)

P549: EFFICACY AND TOXICITY OF CPX-351 IN PATIENTS WITH HIGH-RISK ACUTE MYELOID LEUKEMIA (AML): THE MULTICENTER REAL-WORLD EXPERIENCE FROM THE “ITALIAN TRIVENETO REGISTRY”.
由: Gian Luca Morelli, et al.
出版: (2023-08-01)

Эффективность, безопасность и переносимость гемтузумаба озогамицина в комбинации с FLAG/FLAG-Ida или азацитидином при рецидивах и рефрактерном течении острого миелобластного лейкоза
由: Ирина Гармаевна Будаева, et al.
出版: (2021-07-01)